PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Phenotype | C0028754|obesity |
| Sentences | 15 |
| PubMedID- 25664341 | Prevention of weight gain and treatment of obesity among patients with schizophrenia taking atypical antipsychotics have become a priority in clinical practice and represent a major public health problem [1, 6]. |
| PubMedID- 23570345 | In addition, obesity among patients with schizophrenia is associated with high medication costs[7], low self-esteem, poor psychosocial adaptation[8], non-compliance with an antipsychotic medication regime[9] and reduced quality of life (qol)[10]. |
| PubMedID- 24346756 | The higher prevalence of obesity in patients with schizophrenia is a matter of clinical and public health concern; interventions to reduce weight to healthy levels would result in both improved health and quality of life among patients with schizophrenia. |
| PubMedID- 22554352 | In previous studies that have considered obesity in patients with schizophrenia, weight or body mass index (bmi) was commonly used as measurement parameters. |
| PubMedID- 22523667 | Antipsychotic medications have been considered the primary risk factor for obesity in schizophrenia, although the mechanisms by which they increase weight and produce metabolic disturbances are unclear. |
| PubMedID- 22714874 | The prevalence of obesity among patients with schizophrenia was significantly greater than that in the healthy malaysian population, and affects the 3 main races in malaysia. |
| PubMedID- 23691790 | Aim: many studies have reported a high prevalence of obesity in patients with schizophrenia compared to the general population. |
| PubMedID- 24947974 | The objective of this study was to examine the association between dietary patterns and obesity among patients with schizophrenia in japan. |
| PubMedID- 22131945 | It also explains the common co-occurrence of schizophrenia with addiction, obesity and diabetes. |
| PubMedID- 26016380 | Objective: to review recent advances in the epidemiology, pathobiology, and management of weight gain and obesity in patients with schizophrenia and to evaluate the extent to which they should influence guidelines for clinical practice. |
| PubMedID- 24249923 | A number of explanations like lifestyle and dietary habits that facilitate the development of obesity among patients with schizophrenia, direct antipsychotic drug action on lipid and carbohydrate metabolism,[5] the tendency to accumulate intra-abdominal adiposity and fat,[6] certain alterations of the hypothalamic pituitary-adrenal axis (hpa) producing hypercortisolemia,[7] and its genotypic expression in the form of truncal obesity, poor blood glucose control,[8] and possible associated alterations in hippocampal volume[9] have been proposed. |
| PubMedID- 22997527 | The prevalence of obesity among patients with schizophrenia is increasing each year [5–9]. |
| PubMedID- 26064048 | Given the prevalence of obesity in patients with schizophrenia, it is important to consider the need for dose adjustments or special consideration in obese patients. |
| PubMedID- 20079934 | obesity and smoking in patients with schizophrenia and normal controls: a case-control study. |
| PubMedID- 23805859 | In the northern finland 1966 birth cohort study, rates of obesity in patients with schizophrenia were 42% compared to 13% for rest of the cohort [9]. |
Page: 1